GC Wealth Management RIA LLC Buys 11,760 Shares of Danaher Corporation $DHR

Key Points

• GC Wealth Management RIA LLC significantly increased its holdings in Danaher Corporation by acquiring an additional 11,760 shares, raising its stake by 1,064.3% to a total of 12,865 shares valued at $2,541,000.
• Danaher recently announced a quarterly dividend of $0.32 per share, with the ex-dividend date set for September 26th and an annualized yield of 0.7%.
• Wall Street analysts have given Danaher a favorable outlook, with an average target price of $245.91 and a consensus rating of "Moderate Buy."

GC Wealth Management RIA LLC raised its stake in shares of Danaher Corporation (NYSE:DHR - Free Report) by 1,064.3% during the 2nd quarter, according to its most recent filing with the SEC. The firm owned 12,865 shares of the conglomerate's stock after acquiring an additional 11,760 shares during the period. GC Wealth Management RIA LLC's holdings in Danaher were worth $2,541,000 as of its most recent SEC filing.

Several other hedge funds and other institutional investors have also bought and sold shares of the stock. V Square Quantitative Management LLC lifted its stake in Danaher by 1.6% during the 2nd quarter. V Square Quantitative Management LLC now owns 17,579 shares of the conglomerate's stock valued at $3,473,000 after acquiring an additional 284 shares during the period. Capital Insight Partners LLC lifted its stake in shares of Danaher by 12.8% in the 2nd quarter. Capital Insight Partners LLC now owns 4,173 shares of the conglomerate's stock worth $824,000 after purchasing an additional 475 shares during the period. Global Trust Asset Management LLC lifted its stake in shares of Danaher by 9.3% in the 2nd quarter. Global Trust Asset Management LLC now owns 1,358 shares of the conglomerate's stock worth $268,000 after purchasing an additional 116 shares during the period. Clean Yield Group lifted its stake in shares of Danaher by 7.7% in the 2nd quarter. Clean Yield Group now owns 1,004 shares of the conglomerate's stock worth $198,000 after purchasing an additional 72 shares during the period. Finally, Smith Salley Wealth Management lifted its stake in shares of Danaher by 9.9% in the 2nd quarter. Smith Salley Wealth Management now owns 1,635 shares of the conglomerate's stock worth $323,000 after purchasing an additional 147 shares during the period. Institutional investors own 79.05% of the company's stock.

Wall Street Analysts Forecast Growth

Several brokerages have recently weighed in on DHR. Royal Bank Of Canada set a $241.00 price objective on shares of Danaher in a research note on Tuesday, September 2nd. Guggenheim reissued a "buy" rating and issued a $250.00 target price on shares of Danaher in a report on Wednesday, July 23rd. Barclays reissued an "overweight" rating and issued a $225.00 target price (up from $215.00) on shares of Danaher in a report on Tuesday, June 24th. Evercore ISI reduced their target price on shares of Danaher from $230.00 to $226.00 and set an "outperform" rating for the company in a report on Tuesday, July 8th. Finally, UBS Group reduced their target price on shares of Danaher from $240.00 to $225.00 and set a "buy" rating for the company in a report on Wednesday, July 23rd. Seventeen investment analysts have rated the stock with a Buy rating and three have given a Hold rating to the company. Based on data from MarketBeat.com, the stock presently has an average rating of "Moderate Buy" and an average target price of $245.91.

Danaher Stock Up 1.9%

NYSE DHR opened at $184.97 on Monday. The company has a market capitalization of $132.45 billion, a P/E ratio of 39.36, a P/E/G ratio of 2.63 and a beta of 0.75. The stock has a 50 day moving average price of $199.44 and a 200-day moving average price of $197.48. Danaher Corporation has a one year low of $171.00 and a one year high of $279.59. The company has a debt-to-equity ratio of 0.32, a quick ratio of 1.22 and a current ratio of 1.62.

Danaher (NYSE:DHR - Get Free Report) last issued its quarterly earnings results on Tuesday, July 22nd. The conglomerate reported $1.80 earnings per share (EPS) for the quarter, topping analysts' consensus estimates of $1.64 by $0.16. Danaher had a return on equity of 10.70% and a net margin of 14.21%.The company had revenue of $5.94 billion during the quarter, compared to the consensus estimate of $5.83 billion. During the same period last year, the company earned $1.72 earnings per share. Danaher's revenue was up 3.4% on a year-over-year basis. Danaher has set its FY 2025 guidance at 7.700-7.800 EPS. As a group, equities analysts predict that Danaher Corporation will post 7.63 EPS for the current fiscal year.

Danaher Announces Dividend

The firm also recently announced a quarterly dividend, which will be paid on Friday, October 31st. Stockholders of record on Friday, September 26th will be given a dividend of $0.32 per share. This represents a $1.28 annualized dividend and a dividend yield of 0.7%. The ex-dividend date is Friday, September 26th. Danaher's dividend payout ratio (DPR) is 27.23%.

Insider Buying and Selling at Danaher

In other news, Director Teri List sold 2,778 shares of Danaher stock in a transaction on Friday, August 22nd. The stock was sold at an average price of $211.06, for a total transaction of $586,324.68. Following the completion of the sale, the director directly owned 20,751 shares in the company, valued at approximately $4,379,706.06. This trade represents a 11.81% decrease in their ownership of the stock. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which can be accessed through this link. Company insiders own 11.20% of the company's stock.

About Danaher

Danaher Corporation designs, manufactures, and markets professional, medical, industrial, and commercial products and services worldwide. The Biotechnology segments offers bioprocess technologies, consumables, and services that advance, accelerate, and integrate the development and manufacture of therapeutics; cell line and cell culture media development services; cell culture media, process liquids and buffers for manufacturing, chromatography resins, filtration technologies, aseptic fill finish; single-use hardware and consumables and services, such as the design and installation of full manufacturing suites; lab filtration, separation, and purification; lab-scale protein purification and analytical tools; reagents, membranes, and services; and healthcare filtration solutions.

Want to see what other hedge funds are holding DHR? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Danaher Corporation (NYSE:DHR - Free Report).

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest and most accurate reporting. This story was reviewed by MarketBeat's editorial team prior to publication. Please send any questions or comments about this story to contact@marketbeat.com.